Personalized Melanoma Vaccine Shows 42% Reduction in Recurrence Risk in Clinical Trial
Source Summary
Merck and Moderna announced clinical trial results for intismeran, a personalized melanoma vaccine that, when combined with immunotherapy, reduced the risk of cancer recurrence or death by 42% compared with immunotherapy alone. The vaccine represents a potential major advance in cancer treatment approaches.
Why it matters
A 42% reduction in recurrence or death risk represents a clinically significant improvement that could expand treatment options for melanoma patients and inform broader cancer vaccine development.
